Abstract:Abstract Patients with metastatic breast cancer (MBC) have a dismal prognosis, with a 5-year survival rate of only 26%. The inadequate infiltration of immune cells targeting the tumor microenvironment (TME) is a key factor contributing to this low survival rate. Immune effector cells, including CD8+ cytotoxic T cells, NKT cells, and NK cells, play a crucial role in targeting tumor cells. The activation of immune effector cells relies on the presence of conventional type I dendritic cells (cDC1), which present tumor-specific antigenic peptides on their surface. Recent studies have identified the chemokine XCL1 and growth factor FLT3L as critical factors involved in the intratumoral recruitment and expansion of dendritic cells. To enhance the activity of cDC1 in the TME we designed an oncolytic herpes simplex virus (oHSV) expressing XCL1 and FLT3L. The recombinant oHSV, rQ1-XF, was generated by incorporating LoxP sites into the viral genome through recombination with a carrier plasmid carrying the polycistronic cassette. To enhance the intratumoral penetration of oHSV injected intravenously in primary tumors and MBC lesions in the lung, we employed the cancer drug ganetespib, which can increase the permeability of tumor blood vessels. In comparison to untreated mice, ganetespib combined with rQ1-XF reduced the size of primary tumors and induced a short but significant increase in the survival of mice. Additionally, compared to the ganetespib alone treatment, ganetespib combined with rQ1-XF reduced MBC burden in the lung. The flow cytometry analysis of immune cells revealed an increased infiltration of CD11c+CD11b- dendritic cells in primary tumors treated with oHSV combination therapy compared to the ganetespib only control. A similar trend was also observed in CD4 T cells and CD8 T cells in primary tumors. As expected, there was a negative correlation between tumor burden and the infiltration of CD4+ T cells and CD8+ T cells in primary tumors. Ganetespib combined with oHSV also reduced the infiltration of CD4+ regulatory T cells (Tregs) in primary tumors, however the number of Tregs increased with primary tumor size as well as tumor burden in the lung. This could potentially lead to reduced efficacy of tumor-infiltrating dendritic cells in activating effector T cells in tumors treated with ganetespib and rQ1-XF. Moreover, the combination therapy did not yield significant alterations in the populations of DCs, CD4+ T cells, and CD8+ T cells in lungs with metastatic lesions. Further studies are underway to investigate whether the depletion of Treg cells in combination with rQ1-XF enhances effector T cell activation against metastatic breast tumor cells. The findings of this study will provide valuable insights into the effectiveness of using XCL1 and FLT3L-armed oncolytic viruses in patients with MBC. Citation Format: Himanshu Soni, Liqun Gu, Sylvie Roberge, Heena Kumra, Hiroshi Nakashima, E. Antonio Chiocca, Yves Boucher. Oncolytic herpes simplex virus expressing XCL1 and FLT3L modulate the intratumoral immune response and improve the anti-tumor efficacy in a metastatic breast tumor model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6659.

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study

Oncolytic virotherapy stimulates anti‐tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial

Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial

Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial

A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).

Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple Negative Breast Cancer

Intratumoral NKp46+ natural killer cells are spatially distanced from T and MHC-I+ cells with prognostic implications in soft tissue sarcoma

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas

Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma

Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy

Abstract 6659: Oncolytic herpes simplex virus expressing XCL1 and FLT3L modulate the intratumoral immune response and improve the anti-tumor efficacy in a metastatic breast tumor model

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer